Invivyd (NASDAQ:IVVD) CFO William Duke Sells 18,425 Shares

Invivyd, Inc. (NASDAQ:IVVD) CFO William Duke sold 18,425 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $0.84, for a total value of $15,477.00. Following the sale, the chief financial officer owned 168,937 shares of the company’s stock, valued at approximately $141,907.08. This represents a 9.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Invivyd Trading Up 17.2%

IVVD opened at $0.87 on Wednesday. Invivyd, Inc. has a 1-year low of $0.48 and a 1-year high of $3.07. The company has a market cap of $255.75 million, a price-to-earnings ratio of -2.63 and a beta of 0.71. The company’s fifty day moving average price is $0.77 and its two-hundred day moving average price is $1.23.

Invivyd (NASDAQ:IVVD) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. The company had revenue of $14.29 million for the quarter, compared to analyst estimates of $14.40 million. As a group, equities analysts forecast that Invivyd, Inc. will post -0.52 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IVVD has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Invivyd in a research report on Friday, July 24th. HC Wainwright reiterated a “buy” rating on shares of Invivyd in a research note on Tuesday. BTIG Research reiterated a “buy” rating on shares of Invivyd in a research report on Tuesday, July 7th. Finally, Wall Street Zen downgraded Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $8.00.

Key Headlines Impacting Invivyd

Here are the key news stories impacting Invivyd this week:

• Neutral Sentiment: Robert D. Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold shares at prices of approximately $0.72 or $0.84. The sales reduced each insider’s direct holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings state that the transactions were made to cover tax-withholding obligations tied to the vesting of equity awards. Because the sales were not described as discretionary reductions or based on a negative outlook, they are less concerning than open-market sales intended to exit positions. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by multiple insiders may nevertheless create a modest overhang for Invivyd stock, particularly given the company’s small market capitalization and recent elevated trading volume. However, the disclosed tax-related purpose limits the bearish signal.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Jupiter Topco LLC bought a new position in Invivyd during the 2nd quarter worth approximately $30,048,000. Janus Henderson Group PLC lifted its position in shares of Invivyd by 1.7% in the 1st quarter. Janus Henderson Group PLC now owns 33,094,330 shares of the company’s stock worth $42,857,000 after purchasing an additional 551,188 shares during the period. Perceptive Advisors LLC bought a new stake in Invivyd during the 4th quarter valued at approximately $53,809,000. BVF Inc. IL bought a new stake in shares of Invivyd during the fourth quarter valued at approximately $48,227,000. Finally, RA Capital Management L.P. purchased a new stake in shares of Invivyd in the 3rd quarter worth about $18,831,000. 70.36% of the stock is owned by institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.